Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Drug Administration Schedule
Female
Humans
Indazoles
Interleukin-10
Kidney Neoplasms
Male
Middle Aged
Polyethylene Glycols
Pyrimidines
Sulfonamides
Survival Analysis
Treatment Outcome
Young Adult

authors with profiles

Raid Aljumaily